Prelude Therapeutics: Leading the Oncology Market With Innovative SMARCA2 Targeting Drug PRT3789

TipRanksApr 26 02:05

Prelude and Loyal: Collaborating to Extend Canine Lifespans

AUSTIN, Texas, April 19, 2024 /PRNewswire/ -- Loyal, the San Francisco-based company dedicated to improving the health and longevity of dogs, and Prelude, the leading animal health-focused electronic

PR NewswireApr 20 02:48

Several Insiders Invested In Prelude Therapeutics Flagging Positive News

Yahoo FinanceApr 13 21:54

Prelude Therapeutics Announces CFO Transition and Interim Appointment

TipRanksApr 11 04:24

Prelude Therapeutics Disclosed Laurent Chardonnet Will No Longer Serve As CFO

Prelude Therapeutics Disclosed Laurent Chardonnet Will No Longer Serve As CFO

BenzingaApr 11 04:11

Prelude Therapeutics: A Buy Rating on the Horizon With Promising Preclinical Data and Upcoming Clinical Trials

Prelude Therapeutics (PRLD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Reni Benjamin from JMP Securities reiterated a Buy rating on the stock and has a $7.00 price target.

TipRanksApr 11 02:35